Mynewsdesk LinkedIn

The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®.

Affibodys latest Press releases

To the archive

2023-01-05

Positive Top-line Clinical Data for Izokibep in Hidradenitis Suppurativa

Solna, Sweden, January 5, 2023. Affibody’s partner ACELYRIN, Inc. today announced top-line 12-week open label data from a Phase 2b/3 trial of izokibep in...[read more]

2023-01-04

First HER2-low patients enrolled in Phase 2 basket trial using Affibody’s...[read more]

2022-12-23

Affibody signs €20 million loan agreement with the EIB to finance...[read more]

Affibody’s proprietary technology offers several key advantages over current targeted approaches

Research & Development

Multi-specific formats enabling bi-specific binding and extended half-life

Site-specifically modified drug conjugates with excellent tox profile and high tumor uptake

Biodistribution flexibility and good tissue penetration to reach targets that are difficult to reach for antibodies